Drugs / HER-2/neu intracellular domain protein
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT00005956 | Feb 2000 → Aug 2001 | breast cancer, gastric cancer, ovarian cancer | Duke University | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HER-2/neu intracellular domain protein | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00005956 ↗ |
| Action | Deplete | “A person's white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells” NCT00005956 ↗ |
| Modality | Protein / enzyme biologic | “vaccination with HER2 ICD protein-containing DC” PMID 17822557 ↗ Sep 2007 |
| Route | Subcutaneous | “The pulsed DC are administered subcutaneously (SQ) and intradermally” NCT00005956 ↗ |
| Target | ERBB2 | “cancer vaccines to stimulate HER2 intracellular domain (ICD)-specific T cell and antibody responses” PMID 17822557 ↗ Sep 2007 |